Sold as Fansidar. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Pyrimethamine; Sulfadoxine (sold as Fansidar), first approved Oct 28, 1981, with 0 new uses approved and 0 published complete response letters.
| Perennial Malaria Chemoprevention in the Malaria Vaccine EraMalaria, Falciparum · Stanford University | Phase 4 | Not yet recruiting | Jan 7, 2026 |
| Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute MalnutritionSevere Acute Malnutrition, Cognitive Impairment · Washington University School of Medicine | Not applicable | Active, not recruiting | Mar 11, 2025 |
| Perennial Malaria Chemoprevention (PMC) Effect StudyMalaria · Malaria Consortium | Not applicable | Active, not recruiting | Dec 4, 2023 |
| Improving Cognition and Gestational Duration With Targeted NutritionMalnutrition in Pregnancy, Preterm Birth · Washington University School of Medicine | Not applicable | Active, not recruiting | Jul 17, 2023 |
| Community-based, Controlled, Open-label, Cluster-randomized Trial for the Reduction of Chronic Malnutrition in Children Under Two Years of Age, With Three Intervention Arms Grouped by Clusters, in Two Provinces in Southern Angola, Huíla and Cunene.Malnutrition, Child · Hospital Universitari Vall d'Hebron Research Institute | Not applicable | Active, not recruiting | Oct 7, 2022 |
| Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in PregnancyMalaria, Malaria in Pregnancy · Menzies School of Health Research | Phase 3 | Active, not recruiting | Jun 22, 2022 |
| Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm BirthMalaria, Sexually Transmitted Diseases · Tampere University | Phase 3 | Active, not recruiting | Aug 17, 2005 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA